Trial 9L-16-18


PhII-145 A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Anti-Angiogenesis
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Mojtaba Akhtari, M.D.
Other Trial Staff:  Ashot Minasyan, D.M., Christine Duran, Coordinator, Donna Fernando, Coordinator, Meena Ibrahim, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.